
Mika
A digital companion for cancer patients by empowering them.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
investor investor | €0.0 | round | |
* | €10.0m | Series A | |
Total Funding | 000k |
USD | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Mika, operating under Fosanis GmbH, is a Berlin-based digital health company established in 2017. The company was founded by Dr. Gandolf Finke and Dr. Jan Simon Raue, who were personally motivated to address the lack of accessible support for cancer patients after loved ones went through the disease. Dr. Finke has an engineering background from Karlsruhe and MIT with a PhD from ETH Zurich and prior experience in healthcare consulting, while Dr. Raue has a background in entrepreneurship, consulting, and science.
The company's core offering is the Mika app, a digital therapeutic (DTx) platform designed to support cancer patients through their treatment journey. The app functions as a digital companion, providing personalized guidance to help patients manage the psychological and physical challenges of cancer. Key features include tools for tracking symptoms and side effects, medication and appointment reminders, and a library of expert-verified articles on treatment options and nutrition. The platform also offers programs for mental health support, such as guided mindfulness journeys and relaxation exercises, aimed at reducing anxiety, depression, and fatigue. This content is developed in partnership with leading oncological research institutions, including Berlin's Charité Hospital and Leipzig University Hospital.
Mika's business model has evolved. Initially, the company aimed for reimbursement through Germany's Digital Health Application (DiGA) framework, which allows doctors to prescribe certified medical apps to patients covered by public health insurance. Mika became the first DiGA approved for all types of cancer in 2021. However, the company later withdrew from the DiGA directory, with the founder citing roadblocks with insurers, and shifted its strategy to B2B partnerships. The app is now offered for free to patients and caregivers in the United States through a partnership with the Cancer Support Community. The company also collaborates with pharmaceutical firms. In June 2025, Boston-based Outcomes4Me announced the acquisition of the Mika Health app's assets from Fosanis GmbH, aiming to combine Mika's emotional support technology and European presence with its own platform to create a more comprehensive digital companion for cancer patients globally.
Keywords: digital therapeutics, DTx, oncology, cancer care, patient support, psycho-oncology, mental health, symptom tracking, Fosanis GmbH, digital health app, Gandolf Finke, Jan Simon Raue, cancer patient companion, therapy management, clinically validated, DiGA, medical device app, health technology, mindfulness, patient empowerment, treatment adherence, side effect management, AI in healthcare, mobile health